>

Publications and resources

>

EU Pharmaceutical legislation

EU PHARMACEUTICAL LEGISLATION

In order to ensure regular access to plasma medicines for those in need, it is critical that policymakers acknowledge the clinical urgency for increased plasma collection in Europe. Discover the latest updates on legislation surrounding the broader European plasma donation ecosystem.

3d shape in blue, customized according to PPTA's branding

3d shape in blue, customized according to PPTA's branding

3d shape in blue, customized according to PPTA's branding

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

PPTA position paper on Stockpiling: EU needs effective measures to facilitate access to lifesaving medicines made of human plasma (PDMPs)

This is some text inside of a div block.

This is some text inside of a div block.

PPTA position paper on Stockpiling: EU needs effective measures to facilitate access to lifesaving medicines made of human plasma (PDMPs)

EU pharmaceutical legislation

This is some text inside of a div block.

PPTA feedback to the revision of the EU Pharmaceutical legislation Inception Impact Assessment

PPTA feedback to the revision of the EU Pharmaceutical legislation Inception Impact Assessment

This is some text inside of a div block.

This is some text inside of a div block.

PPTA feedback to the revision of the EU Pharmaceutical legislation Inception Impact Assessment

PPTA feedback to the revision of the EU Pharmaceutical legislation Inception Impact Assessment

EU pharmaceutical legislation

This is some text inside of a div block.

PPTA feedback to the EU Pharmaceutical Strategy Inception Impact Assessment

The Plasma Protein Therapeutics Association (PPTA) welcomes the Commission’s initiative to help ensure EU’s supply of safe and affordable medicines to meet patients’ needs and reinforce EU’s pharmaceutical industry competitiveness.

This is some text inside of a div block.

This is some text inside of a div block.

PPTA feedback to the EU Pharmaceutical Strategy Inception Impact Assessment

The Plasma Protein Therapeutics Association (PPTA) welcomes the Commission’s initiative to help ensure EU’s supply of safe and affordable medicines to meet patients’ needs and reinforce EU’s pharmaceutical industry competitiveness.

EU pharmaceutical legislation

This is some text inside of a div block.

EU Regulation (EC) No 726/2004]

Consolidated text: Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency (Text with EEA relevance)Text with EEA relevance

This is some text inside of a div block.

This is some text inside of a div block.

EU Regulation (EC) No 726/2004]

Consolidated text: Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency (Text with EEA relevance)Text with EEA relevance

EU pharmaceutical legislation

This is some text inside of a div block.